About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia

NCT00314288·51 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

EMD Serono

Age

30–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Male or Female
The subject is an out-patient
Age 30 years or above
Dyskinesias present during more than 25% of the waking day
Dyskinesias at least moderately disabling
Written informed consent

You may not be if

Pregnancy and/or lactation
Participation in another study within the last 30 days
Dementia or other psychiatric illness that prevents provision of informed consent
History of allergic disorders such as asthma
Known hypersensitivity to the study treatment(s)
Known hypersensitivity to ACTH

The record

StatusCompleted

PhasePhase 2

Taking part360

StartedJul 2002

UpdatedJan 23, 2017

Conditions

Parkinson's Disease Dyskinesia

Where51

Fountain Valley, California, United States
Sunnyvale, California, United States
Miami, Florida, United States

Clareo Health | Sarizotan in Parkinson Patients With L-dopa-induced Dyskinesia